Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis

AMGEN INC.0 个研究点目标入组 500 人开始时间: 2012年12月21日最近更新: 2015年3月23日

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方
入组人数: 500

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•Subject understands the study procedures and agrees to participate in the study by giving written informed consent. • Subject is 18 years of age or older. • Female subjects who are post menopausal (post menopausal is defined as no menses for the previous 1 year and over the age of 50 years), surgically sterilized, have a medical condition that prevents pregnancy,remain abstinent, or are willing to use highly effective contraception during the study and for 3 months after the last dose. Women of childbearing potential must have a negative serum pregnancy test within 2 weeks prior to the first dose of investigational product. • Male subject is willing to use highly effective contraception when sexually active and will not donate sperm during the treatment phase and for 3 months after the last dose. • Subject receiving active vitamin D sterols must have had no more than a maximum dose change of 50% within the 2 months prior to screening laboratory assessments, remain stable through randomization, and be expected to maintain stable doses for the duration of the study. • Subject receiving phosphate binders must have had no more than a maximum dose change of 50% within the 2 months prior to screening laboratory assessments, remain stable through randomization, and be expected to maintain stable dose for the duration of the study. • Subject receiving calcium supplements must have had no more than a maximum dose change of 50% within the 2 months prior to screening laboratory assessments and remain stable through randomization. • Subject must be receiving hemodialysis 3 times weekly for at least 3 months and have adequate hemodialysis with a delivered Kt/V = 1.2 or urea reduction ratio (URR) = 65% within 4 weeks prior to screening laboratory assessments. • Dialysis prescription dialysate calcium concentration must be = 2.25 mEq/L and stable for at least 4 weeks prior to screening laboratory assessments, remain stable through randomization and remain = 2.25 mEq/L for the duration of the study. • Subject must have 2 consecutive screening predialysis serum iPTH labs drawn on separate days within 2 weeks prior to randomization and the results of both must be > 400 pg/mL. Enrollment of subjects with mean screening iPTH > 1000 pg/mL will be limited to no more than 20% of subjects. • Subject must have 2 consecutive screening predialysis serum cCa labs drawn on separate days within 2 weeks prior to randomization and the results of both must be = 8.3 mg/dL. • Subject agrees to not participate in another study of an investigational agent during the study. • Subject's legally acceptable representative has provided informed consent when the subject has any kind of condition that, in the opinion of the Investigator, may compromise the ability of the subject to give written informed consent.
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 350
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 150

排除标准

•Currently receiving treatment in another investigational device or drug study, or ended treatment on another investigational device or drug study(s) within 8 weeks prior to screening. • Other investigational procedures while participating in this study are excluded. • Anticipated or scheduled parathyroidectomy during the study period. • Subject has received a parathyroidectomy within 3 months prior to dosing. • Anticipated or scheduled kidney transplant during the study period. • Subject has known sensitivity to any of the products or components to be administered during dosing. • Subject has previously entered this study. • Subject has participated in a prior clinical trial of AMG 416 (also referred to as KAI-4169). • Subject has received cinacalcet within the 4 weeks prior to screening labs (treatment with cinacalcet is prohibited during the study). • Subject has an unstable medical condition based on medical history, physical examination, and routine laboratory tests, or is otherwise unstable in the judgment of the Investigator. • Subject has a history of any illness that, in the opinion of the Investigator, might confound the results of the study or pose additional risk to the subject. • Subject history of malignancy within the last 5 years (except nonmelanoma skin cancers, or cervical carcinoma in situ). • Subject has a serious concurrent medical condition (eg, malignancy) likely to result in death during the next 12 months. • Subject is pregnant or nursing. • Subject has a history of symptomatic ventricular dysrhythmias or Torsades de Pointes. • Subject's screening 12-lead electrocardiogram (ECG) suggests unstable arrhythmia or other cardiac abnormality that could place the subject at increased risk, based upon the Investigator's opinion. • Subject has a history of poorly controlled hypertension (eg, persistent or recurrent postdialysis systolic blood pressure (SBP) > 180 mmHg or DBP > 110 mmHg during the 3 months prior to screening). • Subject has a history of angina pectoris with symptoms that occur at rest or minimal activity or a history of congestive heart failure (New York Heart Association Classification III or IV). • Subject has a history of myocardial infarction, coronary angioplasty, or coronary arterial bypass grafting within the past 6 months prior to screening. • Subject is receiving treatment for a seizure disorder or has a history of a seizure within the last 12 months prior to screening. • Subject has had surgery (except minor surgery) within the last 8 weeks prior to screening. • Subject has clinically significant abnormalities on prestudy clinical examination or central laboratory tests during the 4 weeks prior to randomization according to the Investigator including but not limited to the following: - Serum albumin = 3.0 g/dL - Serum magnesium < 1.5 mg/dL - Hemoglobin < 8.5 g/dL - Platelet count < 100,000 x106/L - Serum transaminase (alanine transaminase [ALT] or Serum glutamic pyruvic transaminase [SGPT], aspartate aminotransferase [AST] or serum glutamic oxaloacetic transaminase [SGOT]) > 2.5 times the upper limit of normal (ULN) at screening • Subject likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures to the best of the subject and Investigator's knowledge. • History or evidence of any other clinically significant disorder, condition or disease (with the except

研究者

发起方

AMGEN INC.

相似试验

招募中

3 期

Randomised, Double-blind, Placebo-controlled, Phase IIIStudyof Olaparib Maintenance Monotherapy in Participants withBRCA Wild Type Advanced (FIGO Stage III-IV) High GradeSerous or Endometrioid Ovarian Cancer Following Response toStandard First-line Platinum-basedChemotherapy(MONO-OLA1C56 Malignant neoplasm of ovaryMalignant neoplasm of ovary

PER-034-21AstraZeneca AB69

进行中（未招募）

1 期

A clinical trial to study the efficacy and safety of an investigational medication, beloranib, in treatment of food-related behaviour and weight in obese individuals with Prader-Willi Syndrome by comparison with placeboImprovement of Hyperphagia and related behaviors as well as Body Composition/Overweight in Prader-Willi-SyndromeMedDRA version: 18.0Level: PTClassification code 10036476Term: Prader-Willi syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disorders

EUCTR2015-000660-33-BEZafgen Inc.150

进行中（未招募）

不适用

EUCTR2015-000660-33-SEZafgen Inc.150

进行中（未招募）

1 期

EUCTR2015-000660-33-ESZafgen Inc.150

进行中（未招募）

1 期

A clinical trial to study the efficacy and safety of an investigational medication, beloranib, in treatment of food-related behaviour and weight in obese individuals with Prader-Willi Syndrome by comparison with placeboImprovement of Hyperphagia and related behaviors as well as Body Composition/Overweight in Prader-Willi-SyndromeMedDRA version: 18.1 Level: PT Classification code 10036476 Term: Prader-Willi syndrome System Organ Class: 10010331 - Congenital, familial and genetic disorders

EUCTR2015-000660-33-FRZafgen Inc.150